NCT05975450View on ClinicalTrials.gov

Subcutaneous Abatacept in Renal Transplant Recipients

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

February 14, 2025

Study Completion Date

February 14, 2025

Conditions
Kidney Transplant Recipient
Interventions
DRUG

Abatacept 125Mg/Ml Syringe

"Participants on qualifying belatacept regimen (with low dose tacrolimus, mmf and prednisone) will have their maintenance regimen changed from i.v. belatacept to s.c. abatacept, which will continue through week 52 (month 12) post-transplant:~Costimulation blockade:~\- Abatacept 125 mg subcutaneous weekly"

Trial Locations (2)

30322

Emory Clinic, Atlanta

Emory Hospital, Atlanta

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Idelberto Badell

OTHER

NCT05975450 - Subcutaneous Abatacept in Renal Transplant Recipients | Biotech Hunter | Biotech Hunter